Ketalar

Quick links to important sections

Ketalar

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketalar

Property Description
Active ingredient Ketamine hydrochloride
Form Sterile solution for injection/infusion
Pharmacological class General Anesthetic, Dissociative Anesthetic
Common purpose Inducing profound analgesia and anesthesia
Origin Synthetic compound (Cyclohexanone derivative)

What Type of Medicine is Ketalar? (Identity and Classification)

Ketalar is the brand designation for a prescription-only medication whose active ingredient is Ketamine, supplied as Ketamine hydrochloride. It is classified as a General Anesthetic and is uniquely categorized as a Dissociative Anesthetic. This classification underscores its unique mechanism as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a vital pathway for signal transmission in the central nervous system. The medication is a synthetic compound that is clinically recognized for its ability to induce a rapid anesthetic state. Ketamine has been recognized as an Essential Medicine since 1985, confirming its importance in global health systems.


Composition and Physical Form (Preparation and Structure)

The standard preparation of Ketalar is a sterile solution for injection or infusion, formulated for parenteral administration via the intravenous (IV) or intramuscular (IM) route, and is often packaged in multiple-dose vials. The active substance, Ketamine hydrochloride, is dissolved in an aqueous base, such as water for injection, and may contain a preservative to maintain product integrity. This injectable liquid form is a distinguishing feature necessary for ensuring the rapid systemic availability required for acute care, allowing medical professionals to quickly induce a controlled anesthetic state.


Core Purpose: Inducing the Dissociative State (Function)

The fundamental purpose of Ketalar is to induce a state of dissociative anesthesia, effectively achieving profound analgesia and a temporary detached awareness of the surroundings. This function is particularly valued in procedural medicine because the drug's mechanism is known to facilitate pain relief and sedation while simultaneously allowing the patient to maintain essential protective reflexes, such as spontaneous respiration and laryngeal function. The ability to sustain these vital reflexes under anesthesia provides a significant clinical advantage in various settings.

Regulatory References

  1. WHO Essential Medicines List for Ketamine
  2. NIH Review on Ketamine's Protective Reflexes

What side effects are possible with Ketalar?

Possible Side Effects and Safety Information

The safety profile of Ketalar (ketamine hydrochloride) is officially documented by government regulatory bodies and highlights several categories of adverse reactions and safety restrictions.

Key Adverse Reactions

The most frequently observed adverse reactions are Emergence Reactions, which occur in approximately 12 percent of patients. These involve psychological changes such as vivid dreams, hallucinations, confusion, excitement, or feelings of unreality. Also frequently observed is a temporary increase in blood pressure and pulse rate.

Serious and Organ-Specific Risks

Serious Adverse Reactions include severe Respiratory Depression or Apnea (cessation of breathing), especially following rapid intravenous administration or overdosage, and Laryngospasm (airway obstruction). Significant fluctuations in blood pressure and heart rate may also pose a risk of Cardiac Decompensation.

Risks related to long-term or chronic use (e.g., associated with abuse or use exceeding several days) include severe toxicity to the urinary and renal systems (such as hemorrhagic cystitis and acute kidney injury) and Hepatotoxicity (liver injury).

Safety Restrictions and Considerations

  • Contraindications: The medicine is strictly contraindicated in patients where a significant increase in blood pressure would be hazardous, such as those with severe or poorly controlled hypertension or serious cardiovascular disease.
  • Administration: Intravenous dosing must be administered slowly (over 60 seconds) to minimize the risk of respiratory side effects.
  • Pediatric Consideration: Regulatory documents advise caution regarding the potential for long-term cognitive deficits (neurotoxicity) when the drug is used for longer than three hours in children under three years of age.
  • Post-Procedure: Patients are officially restricted from driving or operating hazardous machinery for at least 24 hours after receiving the medicine.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Ketamine, typically resulting from doses exceeding those approved for clinical use or from rapid intravenous administration, requires immediate emergency medical care.

Manifestation Official Regulatory Description
Respiratory Function Manifests as respiratory depression, which may progress to the life-threatening outcome of apnea (cessation of breathing). Prolonged depression (extended recovery) is officially documented.
Vascular System Officially cited signs include severe hypertension (elevated blood pressure) and tachycardia (rapid heart rate) which indicate hemodynamic instability.
Other CNS Events Seizures and laryngospasm are documented complications that require appropriate symptomatic treatment within the emergency setting.

Mandated Emergency Actions

Regulatory labeling mandates that emergency medical care must be sought immediately for a confirmed or suspected overdose. Management is strictly symptomatic and supportive, as the official prescribing information states that no specific pharmacological antidote is known. Treatment priorities focus on providing essential physiological support, including securing a patent airway and ensuring adequate ventilation. Due to the risk of vital sign instability and prolonged effects, close hospital monitoring is required until all clinical manifestations have fully resolved.

Therapeutic Uses of Ketalar

Ketalar is an essential medication primarily utilized to induce a temporary change in consciousness, a state often required before specific surgical and diagnostic procedures. This capability helps medical teams safely proceed with necessary care. It is also an important option for supporting effective management of severe, acute discomfort, particularly in time-sensitive situations like emergency settings or when addressing breakthrough pain.

Its primary indicated uses include: anesthesia induction, analgesia, and sedation for procedures. Additionally, healthcare providers may consider this medication to support patients with certain difficult-to-treat chronic discomfort or as a component of treatment for select mood disorders. By addressing intense discomfort, Ketalar may help facilitate necessary medical procedures or physical therapy, which are vital for restoring mobility and supporting a return to regular functional activities.

“This medication is a widely recognized and beneficial option within comprehensive pain management protocols.”


Quick Fact: Supportive Relief for Procedures Ketalar may be used to provide supportive relief and sedation necessary for safely conducting diagnostic tests and minor surgical procedures.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ketalar?

The eligibility to use Ketalar (ketamine hydrochloride) is strictly defined by regulatory documents, which establish the populations approved for use and those for whom use is contraindicated.

Category Official Regulatory Status
Populations for whom use is allowed Approved for use in the general adult population and pediatric patients (children and infants).
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or for whom a significant elevation of blood pressure or heart rate would constitute a serious hazard. This includes specific conditions like severe coronary or myocardial disease and aneurysmal disease.
Age-related eligibility rules Approved for all age groups, but dose selection for older adults should be cautious due to a higher frequency of decreased organ function.
Condition-specific eligibility rules Use requires caution and monitoring in patients with hypertension, liver impairment (due to prolonged effect risk), increased intracranial pressure, and a history of severe psychiatric illness.
Pregnancy and lactation eligibility status Safe use during pregnancy has not been established; use is not recommended. Caution is advised during lactation as it is not known if the drug is excreted in human milk.

The official eligibility profile prohibits use for patients facing serious cardiovascular risks or hypersensitivity. The label mandates caution for conditional use in patients with compromised hepatic or neurological status, guiding professionals on when to restrict or carefully monitor administration.

What should I know about interactions with other medicines?

The official interaction profile for Ketalar (Ketamine Hydrochloride) is structured around both pharmacodynamic and pharmacokinetic effects, defining specific substance classes that alter the drug's activity or clearance.

Co-administration with other Central Nervous System (CNS) depressants, including benzodiazepines and opioid analgesics, may result in an additive effect, leading to profound sedation and respiratory depression. Pharmacodynamic interactions also include an enhanced pressor effect when used with sympathomimetics, vasopressin, or thyroid hormones, which may increase the risk of hypertension and tachycardia.

Regarding regulatory restrictions, official labeling prohibits the co-administration of Theophylline or Aminophylline due to the potential risk of lowering the seizure threshold. Additionally, the physical mixing of the injection solution with agents like Barbiturates or Diazepam is strictly forbidden due to chemical incompatibility and precipitate formation.

From a pharmacokinetic standpoint, certain medicines classified as CYP3A4 inhibitors (such as specific antifungals) can decrease the hepatic clearance of the drug. This alteration in metabolic processing may increase the plasma concentrations of the active ingredient, as noted in official prescribing information. Finally, regulatory documents advise caution when the medication is administered to a patient who is acutely or chronically alcohol-intoxicated.

Mechanism of Action

Mechanism of Action: How Ketalar Works

Targeting the Glutamatergic System: Dissociation and Nociceptive Inhibition

Ketalar works primarily as a non-competitive antagonist of the N-methyl-D-aspartate receptor (NMDA-R), the main receptor for the excitatory neurotransmitter glutamate. By blocking the flow of ions through this channel, it selectively interrupts communication between the thalamus and cortex, leading to the drug's characteristic dissociative state and intense inhibition of nociceptive signaling (pain transmission).

Modulating Synaptic Plasticity and Neurotrophic Factors

The initial NMDA blockade triggers a downstream cascade by disinhibiting local neurons, causing a surge of glutamate that activates other receptors, such as AMPA receptors. This process activates pathways like mTOR and enhances the release of BDNF. These mechanisms result in the formation of new synaptic connections (neuroplasticity), affecting long-duration modulation of cellular function.

Sympathetic Stimulation and Secondary Receptor Modulation

In addition to its primary action, Ketalar affects other systems by inhibiting the reuptake of norepinephrine and acting as an antagonist at muscarinic acetylcholine receptors. These secondary mechanisms result in the potentiation of catecholamine activity, leading to a sympathomimetic effect that increases heart rate and blood pressure. This action adjusts cardiovascular output.

Dosage and Administration Information

How to Use Ketalar (Ketamine Hydrochloride)

Ketalar is a drug strictly administered in a clinical setting by or under the direct supervision of a trained healthcare professional, such as an anesthesiologist, with continuous monitoring and immediate availability of resuscitation equipment.

Administration and Dosage

Ketalar is a sterile solution given only by Intravenous (IV) injection/infusion or Intramuscular (IM) injection. The dosage is always individualized based on the patient's body weight and adjusted (titrated) to achieve the desired clinical effect.

Parameter Instruction Details
IV Induction Dose Ranges from 1 mg/kg to 4.5 mg/kg. The typical dose is 2 mg/kg and must be administered slowly over 60 seconds to avoid adverse effects.
IM Induction Dose Ranges from 6.5 mg/kg to 13 mg/kg, with 10 mg/kg being typical.
Maintenance Doses Administered as needed, typically increments of one-half to the full initial dose repeated by injection, or via continuous IV infusion at rates like 2 mg/kg/hour to 6 mg/kg/hour.

Preparation and Special Conditions

Preparation involves specific steps for patient safety and efficacy. Patients are often premedicated with an anticholinergic agent (e.g., atropine) to reduce excessive salivation caused by ketamine.

For intravenous use, the highly concentrated 100 mg/mL solution must be diluted with an equal volume of a compatible solution (such as 0.9% Sodium Chloride Injection) before injection. Dilution to a concentration of 1 mg/mL is typically required for continuous IV infusion. The drug must be visually inspected before use and is not recommended for children under three months of age.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ketalar

Evidence for Anesthesia and Procedural Sedation

Ketalar was originally studied decades ago as a general anesthetic agent. The foundational research for this approved use included extensive historical clinical trials and observational studies that evaluated Ketalar for use in inducing and maintaining general anesthesia and for procedural sedation and analgesia for short medical procedures. These studies monitored physiological outcomes related to cardiovascular activity and the maintenance of protective airway reflexes in patients undergoing surgery. For procedural sedation, randomized controlled trials (RCTs) monitored Ketalar compared to other methods, focusing on outcomes related to pain intensity scores and time needed for the patient to recover.

What remains uncertain: While the core use for general anesthesia is supported by historical standards, contemporary research is often limited to comparing it with newer agents. For procedural sedation, the evidence is often referenced for these uses, though the ideal dosing schedule and combination of agents continue to be explored in ongoing research.


Evidence for Perioperative and Acute Pain Management

Ketalar was evaluated in numerous randomized controlled trials (RCTs) and meta-analyses for research exploring its use as an adjunct to opioid-sparing protocols for outcomes related to physical discomfort. Studies primarily monitored physical discomfort and opioid consumption.

What the studies reported (neutral summary): Studies reported measurements describing changes in supplemental opioid consumption in the first 24 to 48 hours in the observed populations. However, the evidence relating to patient-reported outcomes describing perceived discomfort was mixed. Research has explored whether its use was associated with changes in measures of longer-term physical discomfort at six months. However, the findings in this area are still emerging and lack consistency across trials.


Long-Term Studies and Follow-Up Data

For the approved uses, the follow-up durations were constrained to the immediate recovery period. Consequently, there is limited information for long-term outcomes following single use. For acute pain management and mood disorders, research is exploring short-term symptom changes, but long-term effects are not fully established. Studies monitoring these patient groups over extended intervals remain smaller and more limited.


What Is Still Uncertain About Ketalar Research

The research base presents several areas where data remain insufficient or findings were mixed:

  • Optimal Protocol Uncertainty: For both acute pain and mood disorders, researchers are still examining dose-response relationships to determine the ideal administration route and schedule.
  • Neurocognitive Outcomes: Especially in critically ill children and older adults, studies are actively exploring how symptoms change over time concerning long-term neurocognitive and functional outcomes, and certainty remains low for these specific endpoints.

Frequently Asked Questions (FAQ)

Common questions about Ketalar (FAQ)


Q: Is Ketalar the same as ketamine, or is it different?

Ketalar is the brand name designation for the active ingredient ketamine hydrochloride. They refer to the same medication, which is officially categorized as a dissociative anesthetic. The official product information specifies the drug's properties under this brand name.


Q: How quickly does Ketalar start working?

The onset of effect is very rapid, particularly when given intravenously (IV). Official information states that the anesthetic state typically begins within 30 seconds to one minute after an IV dose. The onset is slower when the medication is administered intramuscularly (IM).


Q: How long do the effects of Ketalar typically last?

Following a single intravenous (IV) injection, the anesthetic effect usually lasts for approximately 5 to 10 minutes. The duration of the effect is generally longer when the medication is administered via an intramuscular (IM) injection.


Q: What's the difference between Ketalar and other general anesthetics?

Ketalar is uniquely classified as a dissociative anesthetic. This is due to its distinct action, which typically results in profound pain relief (analgesia) while also allowing the patient to maintain protective airway reflexes and spontaneous respiration. This feature distinguishes it from many other general anesthetic agents.


Q: Can Ketalar cause nausea or vomiting?

Yes, regulatory documents list common side effects that have been reported with Ketalar. Among these commonly observed gastrointestinal side effects are nausea and vomiting.


Q: What should I watch out for after I've been given Ketalar?

A common psychological effect to be aware of is an emergence reaction, which may involve vivid dreams, confusion, or feelings of unreality as the medication wears off. Additionally, official prescribing information advises that patients are restricted from driving or operating hazardous machinery for at least 24 hours after receiving the medication.


Q: Is it normal to feel disoriented after Ketalar wears off?

Yes, feelings of confusion and disorientation are often reported as part of the 'emergence reactions' that affect some patients. These psychological changes typically lessen within a few hours, though they may occasionally persist for up to 24 hours post-procedure.


Q: Can Ketalar make existing psychiatric conditions worse?

Official prescribing information advises healthcare professionals to use caution when administering Ketalar to patients who have a history of severe psychiatric illness. The drug's emergence reactions include temporary symptoms that can be relevant to individuals with pre-existing psychiatric conditions.


Q: Is Ketalar used for pain relief in emergency situations?

Ketalar is officially approved as a general anesthetic agent. While its official indications do not explicitly list general emergency pain relief, its strong analgesic properties have led to its use for acute pain management in emergency settings.


Q: Is Ketalar used in veterinary medicine?

Yes, regulatory and clinical information confirms that the medication is widely used in veterinary medicine. It is approved and utilized for purposes such as restraint, sedation, pain control, and anesthesia in various animal species, including cats and non-human primates.


Q: Has there been recent research on new uses for Ketalar?

Beyond its established use for anesthesia, there is ongoing research into additional applications for the medication. Studies have focused on exploring its role in managing acute and chronic pain and investigating its potential use in addressing psychiatric conditions, such as depression.


Q: Is Ketalar ever used outside of a hospital setting?

The official product labeling requires the medication to be administered strictly in a clinical setting by or under the direct supervision of a trained healthcare professional. The official documentation requires administration to be in a medically controlled clinical environment where resuscitation equipment is available.


Q: Are allergic reactions to Ketalar common?

While hypersensitivity (allergic reactions) is listed as a contraindication—meaning the drug should not be used if you have a known allergy—severe allergic reactions like anaphylaxis are not listed among the most commonly reported adverse events in clinical use.


Q: Is Ketalar used in burn victim care?

Yes, the official labeling for Ketalar lists specific application areas for its use. This includes procedures like debridement and painful dressing changes for patients with burns, as well as use in other superficial surgical and medical procedures.


Q: Do any herbal supplements interact with Ketalar?

Interactions can occur with certain substances that affect the liver enzymes responsible for metabolizing the medication, specifically the CYP3A4 pathway. For instance, certain supplements that affect liver enzymes (CYP3A4), such as St. John's wort, are noted in drug interaction literature as having the potential to affect the efficacy of Ketalar.


Q: What happens if Ketalar is given while a person is taking tranquilizers?

The official interaction profile states that administering Ketalar alongside other Central Nervous System (CNS) depressants, which can include some tranquilizers, may have an additive effect. This means the combined effect could potentially lead to more profound sedation or increase the risk of respiratory depression.


Q: Is the 'K-hole' phenomenon related to how Ketalar works?

The medication is officially classified as a dissociative anesthetic because its primary mechanism of action creates a detached state of profound pain relief and temporary disconnection from one's surroundings. This characteristic dissociative effect is what is colloquially referred to by the term 'K-hole.'


Q: Can Ketalar be administered by non-anesthesiologists?

The regulatory documents require that the drug be used by or under the direction of physicians experienced in administering general anesthetics and in the maintenance of an airway. Specific training is generally required for any healthcare professional administering the drug.


Q: Are there any specific organs Ketalar can damage?

Official information regarding risks associated with chronic or long-term use highlights potential serious toxicity. This can include damage to the urinary and renal systems (such as kidney injury) and the liver (Hepatotoxicity).


Q: Can Ketalar be used in patients with heart conditions?

The medication is contraindicated—meaning it should not be used—in patients for whom a significant increase in blood pressure or heart rate would be hazardous. This includes individuals with conditions like severe or poorly controlled hypertension or certain forms of serious cardiovascular or aneurysmal disease.


Q: Is Ketalar used in treating severe depression in some studies?

While Ketalar is officially approved as an anesthetic, clinical literature confirms that it is being used and studied off-label for patients with refractory or severe depression. Research continues to explore the potential role of ketamine in the treatment of various mood disorders.


Q: Does Ketalar cause any long-term effects on memory?

For its approved single-use anesthetic purposes, long-term data is limited. However, studies focused on individuals who have engaged in heavy or chronic use have reported evidence of associated issues such as spatial memory impairment and other long-term cognitive deficits.


Q: Why is Ketalar considered a better option for certain patients?

The drug is used in specific clinical situations because of its primary properties: it generally preserves protective airway reflexes and it tends to cause cardiovascular stimulation. The ability to stimulate the cardiovascular system can be beneficial for patients with unstable hemodynamic profiles.


Q: What is the recovery time like after receiving Ketalar?

Though the anesthetic effect is short-lived, most patients require close monitoring and are ready to be discharged within approximately 1.5 to 2 hours after an IV dose. However, the residual psychological effects can persist for a few hours, and an official restriction from driving for 24 hours applies.


Q: Does Ketalar cause a loss of muscle control?

The official product information indicates that the drug is associated with maintaining or slightly enhancing normal skeletal muscle tone. However, regulatory reports also note that some patients may experience muscle stiffness, spasms, or tonic-clonic movements.


Q: What is the shelf life of Ketalar?

Official storage guidelines require that the medication be kept at Controlled Room Temperature (20°C to 25°C). The specific expiration date is determined by the manufacturer and is printed on the vial. Additionally, any solution that has been diluted must be used immediately after preparation.

How should Ketalar be stored and disposed of?

Storage and Handling of Ketalar Injection

Ketalar injection must be stored strictly according to the conditions documented in official regulatory labeling.


Storage Requirements

Condition Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F), which is Controlled Room Temperature.
Protection Must be protected from light and must not be frozen.
Packaging Keep the vial in the outer carton.
Stability Diluted solutions must be used immediately after preparation.

Disposal and Child Safety

As a Schedule III controlled substance, Ketalar must be stored out of the sight and reach of children.

Unused portions of the product must be discarded at the end of each session. The disposal of expired or unused Ketalar must be compliant with all federal, state, and local requirements for controlled substances, often requiring the use of designated drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketalar found in:

A-Z Index: